Clinical trial · Interventional
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
NCT00592111CI-TRIAL-00020303completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study Hypothesis: Clinical staging without laparotomy/splenectomy is adequate for children and young adults with Hodgkin's disease who receive chemotherapy as a component of treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin's Disease | Hodgkin Lymphoma | ALIAS | 0.90 |
| Pediatric | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| COPP/ABV | Drug | — | UNRESOLVED |
| intensive chemo with concurrent growth factor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: COPP/ABV
- type
- EXPERIMENTAL
- label
- 2
- interventionNames
- Drug: COPP/ABV
- type
- EXPERIMENTAL
- label
- 3
- interventionNames
- Drug: intensive chemo with concurrent growth factor
Primary outcomes (1)
- measure
- Determine the role of adjuvant low dose involved field radiotherapy in pediatric patients with Hodgkin's disease who attain a complete response following initial chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
* Age less than 21 years at diagnosis * Previously untreated, pathologically confirmed diagnosis of Hodgkin's disease. * Informed patient/parental consent as required by individual institution and in accordance with the Dept of Health and Human Services * Approval of this protocol by the individual institutional Human Subjects Review Committee. * Indicate Hodgkin's disease clinical stage. * Indicate presence or absence of "B" symptoms. * For Stage I and II disease indicate the following: * presence or absence of bulk disease * number of involved nodal regions * presence or absence of hilar adenopathy
References
Publications (0)
Data not yet available
No reference posted for this study.